CHANDLER, Ariz.--(BUSINESS WIRE)--#AZBW--The Arizona Bioindustry Association will honor Avery

Therapeutics Inc. with an AZBio Fast Lane Award at the 2017

Arizona life science and business leaders as well as guests from across

the country will be on hand to applaud the Avery Therapeutics team for

their progress in developing a novel lifesaving medical device to

address heart failure.

More than 26 million people worldwide suffer from heart failure. It is

the number one cause of morbidity and mortality in the developed world.

In the U.S., heart failure results in over $39 billion in treatment

costs annually and there are more than 600,000 new cases of heart

failure each year.

The progression of heart failure results in a 50 percent mortality rate

within 5 years of diagnosis. But what if it didn’t have to be like this?

That is a question being addressed by the team at Avery Therapeutics.

The startup company is based on the application of research from the

University of Arizona. With help from Tech Launch Arizona, the office of

the UA that commercializes inventions stemming from research, Avery

Therapeutics licensed a beating heart graft technology invented at the

UA College of Medicine – Tucson. Pre-clinical studies already have shown

that the technology, called MyCardia™, improves heart function.

After it has FDA approval, doctors will be able to use MyCardia to treat

heart failure by regenerating new heart cells and thus restoring heart

function. Today, no other technology does this except for heart

transplantation.

MyCardia is a cardiac graft containing human induced pluripotent stem

cell-derived cardiomyocytes and human neonatal dermal fibroblasts on a

bioabsorbable scaffold.

MyCardia utilizes Nobel Prize-winning induced pluripotent stem cell

technology and can be cryopreserved so it can be stored in the hospital,

ready to use.

Moving forward faster

MyCardia has the potential to stop the progression of heart failure and

improve patients’ quality of life. It has demonstrated improvements in

heart function in pre-clinical models at levels that would translate to

a significant improvement in quality of life for patients with heart

failure. Avery Therapeutics currently is on track to start clinical

trials with MyCardia in 2020.

The inventors, Steve Goldman, MD, professor of medicine at the UA

Sarver Heart Center, and Jordan Lancaster, PhD, who earned his

doctorate in physiology from the UA College of Medicine – Tucson, serve

as the company’s chief medical and chief science officers, respectively.

Avery Therapeutics’ chief operating officer, Jen Koevary, PhD, earned

her doctorate in biomedical engineering from the UA and previously was

part of the team at Tech Launch Arizona.

The Avery Therapeutics team was awarded a Phase 1 Small Business

Innovation Research (SBIR) award of almost $500,000 from the National

Institutes of Health (NIH), a $750,000 grant from the Arizona Biomedical

Research Commission, $60,000 in cash and prizes at Tucson’s Get Started

pitch competition in October 2016 and $575,000 from a first round of

investment.

A ceremony honoring Avery Therapeutics, Inc., will take place at the AZBio

Awards on Oct. 11 at the Phoenix Convention Center.

The AZBio Awards ceremony celebrates Arizona’s leading educators,

innovators and companies. Each year, AZBio honors bioindustry leaders

from across Arizona who are illustrative of the depth, breadth and

expertise of its bioscience industry. The AZBio Awards ceremony is held

annually during Arizona

Bioscience Week. AZBW 2017 was proclaimed by the Arizona Senate

earlier this year. Multiple educational events focused on the value of

life science innovation will take place from Oct. 8-14, including the BMES

Annual Meeting in Phoenix. The Biomedical Engineering Society (BMES)

is the world’s leading society of professionals devoted to developing

and using engineering and technology to advance human health and

well-being. Attendees at BMES 2017 in Phoenix are expected to include

nearly 4,000 professional scientists, engineers, researchers and

students from academia and industry who are leaders in biomedical

engineering.

###

For registration and more information, go to www.azbioawards.com

For more information on Arizona Bioscience Week, visit www.AZBio.org/AzBW2017

About AZBio

A key component in Arizona’s life science ecosystem, the Arizona

Bioindustry Association (AZBio) is the only statewide organization

exclusively focused on Arizona’s bioscience industry. AZBio membership

includes patient advocacy organizations, life science innovators,

educators, healthcare partners and leading business organizations. AZBio

is the statewide affiliate of the Biotechnology Innovation Organization

(BIO) and works in partnership with AdvaMed, MDMA and PhRMA to advance

innovation and to ensure that the value delivered from life-changing and

life-saving innovation benefits people in Arizona and around the world.

For more information visit www.AZBio.org

Contacts

Arizona Bioindustry Association

Joan Koerber-Walker, 480-332-9636

or

Amanda

Vega, 480-275-9797